Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LSS | P48449 | 3/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9422049 | 0.90 | ALDH1A1 (0.56) | MAPTNPC1HTTMAPK1SMN1; SMN2 | |
| SCHEMBL14099187 | 0.86 | LMNA (0.50) | MAPTNPC1HTTMAPK1KMT2A | |
| SCHEMBL9327289 | 0.83 | AKR1C3 (0.51) | MAPTNPC1HTTMAPK1KMT2A | |
| SCHEMBL10877746 | 0.83 | MAPT (0.71) | MAPTNPC1HTTMAPK1KMT2A | |
| SCHEMBL5307521 | 0.83 | CES2 (0.55) | MAPTNPC1HTTMAPK1KMT2A | |
| SCHEMBL9726681 | 0.82 | CSNK2A1 (0.47) | MAPTNPC1HTTMAPK1KMT2A | |
| SCHEMBL3469362 | 0.81 | CASP3 (0.54) | MAPTNPC1HTTMAPK1KMT2A | |
| SCHEMBL10396945 | 0.80 | MAPT (1.00) | MAPTNPC1HTTMAPK1KMT2A | |
| SCHEMBL9422042 | 0.80 | DGAT1 (0.54) | MAPTNPC1HTTMAPK1KMT2A | |
| SCHEMBL7401884 | 0.80 | LTA4H (0.49) | MAPTNPC1HTTMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150366824-A1 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366824-A1 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | ESRRA, ESRRB, ESRRG | MAPT 4016/4885NPC1 89/4885HTT 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.